Atogepant Reduces Monthly Migraine Days in Phase 3 Prevention Trial
The ADVANCE study included 910 adults who experienced 4 to 14 migraines per month.
Migraine
Managing Chronic Headache During the COVID-19 Pandemic: A Q&A
Matthew Robbins, MD, author of “COVID-19 and headache: a primer for trainees,” details how care has changed for patients with chronic headaches in the midst of the COVID-19 pandemic.
Positive Outcomes Reported With Novel Intranasal DHE for Migraine
Positive results were announced from the phase 3 STOP-301 study evaluating INP104 (intranasal dihydroergotamine mesylate; Impel NeuroPharma) for the treatment of acute migraine in adults.
Galcanezumab Linked to Improved Work Productivity in Patients With Migraine
Galcanezumab was found to significantly improve work productivity and reduce interictal burden in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.
Celecoxib Oral Solution Approved for Acute Migraine Treatment
The FDA has approved Elyxyb (Dr. Reddy’s Laboratories), an oral solution formulation of celecoxib, for the acute treatment of migraine with or without aura in adults.
Ajovy Now Available in Autoinjector Device for Migraine Prevention
Ajovy (fremanezumab-vfrm; Teva) is now available in an autoinjector device for the preventive treatment of migraine in adults.
Novel Meloxicam/Rizatriptan Combo Superior to Placebo in Migraine Trial
Treatment with AXS-07, an investigational therapy being developed by Axsome Therapeutics, substantially reduced migraine pain and significantly prevented the progression of migraine pain intensity, according to results of the phase 3 INTERCEPT trial.
Significant Reduction in Monthly Migraine Days Observed With Rimegepant in Prevention Trial
Biohaven announced positive topline results from a pivotal phase 2/3 study evaluating rimegepant for the preventive treatment of episodic and chronic migraine in adults.
MPR Weekly Dose Podcast Episode 24
This week we talk about the ban on certain electrical stimulation devices, the latest COVID-19 news, a first generic of Daraprim, a New Drug Application for a potential microneedle migraine treatment patch, and a first over-the-counter combination of ibuprofen and acetaminophen.
Fremanezumab Beneficial in Patients With Chronic Migraine, Moderate to Severe Depression
Investigators sought to determine the long-term safety and efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to severe depression.
